Podcasts about Neurology

The Illusion of Optimization: Balancing Physiology and Neurology in Coaching In this episode of the Coaching Coaching Podcast, hosts Steve Magness and John Marcus dive into a deep discussion about the complexities of coaching that lie beyond the modern obsession with optimization. They argue that true coaching success comes from a balance between understanding physiology…

In part two of this series, Dr. Jeff Ratliff discusses the expanding role of AI and digital tools in neurology education, emphasizing the importance of verifying information and developing source literacy.  Show transcript:  Dr. Jeff Ratliff: Hi, this is Jeff Ratliff from Thomas Jefferson University, and this is your Neurology Minute. I recently recorded a podcast episode with Roy Stroud, Justin Abadamarko, and Tisha Monteith, where we discussed the growing impact of technology in neurology education. In this episode, we touched on podcasting, AI-based learning and social media in neurology education, all as a panel discussion. As an accompaniment to that conversation, we're releasing a series of Neurology Minute episodes, exploring those tools. Today I want to focus an important caution, verification. With increasing use of digital tools, AI or otherwise. The need for caution and verification of sources is even more important. Large language models and other AI tools are very frequently used by trainees at all levels. To summarize topics, generate explanations, and even draft a differential diagnosis. But as you all know, the outputs of these tools can be efficient and really impressive, but we need to keep in mind that potential issues with reliability. While less and less common, these tools may hallucinate producing information that sounds authoritative and sounds correct, but it's actually outdated or maybe even unsupported by evidence. So for those of us teaching at the bedside or in clinic, this means we have a responsibility to help our learners develop literacy towards AI and other digital tools. We have to be critics of our sources. As neurologists, we can role model asking questions like, where did this information come from and how do we verify it, and did you read the study that they cited? We encourage trainees to trace these claims back to the primary literature or to pull up guidelines or other trusted review sources just as we do in our own practice. I don't want to pour water on the AI enthusiasm. The truth is still that AI education tools can be a powerful adjunct for learning, but we should treat it like an assistant, not a supervisor. It's useful, it's fast, but it's still in need of our own supervision. Please tune into our podcast discussion to hear more about the rapidly changing landscape of neurology education. Meanwhile, thanks for listening to the Neurology Minute.   

A mini-review published in Frontiers in Neurology suggests that acupuncture may assist ICU patients in recovering more quickly by relieving pain, lowering sedative use, shortening ventilator dependency, enhancing strength, and increasing days free from delirium Acupuncture may help calm inflammation, boost immunity, and improve blood flow in sepsis patients, offering supportive benefits alongside standard ICU treatment It's not just for managing one symptom: Acupuncture could act as a whole-body support tool in the ICU, easing pain, stress, and sleep issues while reducing drug side effects and helping the body recover Emotional Freedom Techniques (EFT) is a needle-free method using fingertip tapping on acupuncture points that offers a gentler alternative for patients wary of traditional acupuncture Other nondrug therapies such as massage, music therapy, and mindfulness contribute to ICU recovery by alleviating anxiety, decreasing pain, and enhancing sleep quality

Dr. Halley Alexadner talks with Dr. Alissa M. D'Gama about genetic testing for infantile epilepsies.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

In part two of this series, Dr. Tesha Monteith and Dr. Andrew Hershey discuss appropriate treatment strategies to prevent migraines in children and adolescents. Show citation:  Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394(3):243-252. doi:10.1056/NEJMoa2504546  Show transcript:  Dr. Tesha Monteith: This is Tesha Monteith with the Neurology Minute. I'm back with Andrew Hershey, professor of Pediatrics and Director of the Division of Neurology at Cincinnati Children's and the Children's Headache Center. This is part two of our discussion on his paper published in the New England Journal of Medicine, fremanezumab in Children and Adolescents with Episodic Migraine. Andrew, now that we have fremanezumab approved for prevention of episodic migraine in children and adolescents, and we have a number of other devices and treatments for patients that can be used as part of FDA-approved treatment or even off-label, can you discuss an appropriate treatment paradigm to prevent migraine? Dr. Andrew Hershey: I think the first and foremost part of the paradigm is to identify the disease, so recognition that headaches are a component of the disease migraine, so you have headaches attacks due to migraine is an essential part. Many of the children, adolescents and their families are unaware that that is even what they're having, and clarifying the etiology actually goes a long way. One of my former mentors, Dr. Prensky, always said that 50% of kids get better from just seeing a child neurologist, and I think it's that clarification of the diagnosis. Second to that, you need to provide a very adequate acute treatment as well as what's probably even more essential than anything else is healthy lifestyle habits. So regular eating, drinking, sleeping, and exercise. And then finally, if the headache is causing severe disability or frequent headaches or interfering with the child's school, home or social life, the prevention medications may need to be added. And this is where the fremanezumab, or if you prefer devices, devices can be used for both the acute and preventive treatment. Dr. Tesha Monteith: Well, thank you for the summary, and congratulations again on your paper. Dr. Andrew Hershey: Thank you. Dr. Tesha Monteith: Do check out the full podcast for more details about the paper and treatment of migraine in children and adolescents. This is Tesha Monteith. Thank you for listening to the Neurology Minute.

Dr. Greg Cooper and Dr. David G. Coughlin discuss the role of αSyn-SAAs in diagnosing DBL and their relationship with Alzheimer's disease biomarkers.  Show citation: Coughlin DG, Jain L, Khrestian M, et al. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression. Neurology. 2025;105(12):e214346. doi:10.1212/WNL.0000000000214346 Show transcript:  Dr. Greg Cooper: Hi, this is Dr. Greg Cooper. I just finished interviewing Dr. David Coughlin for this week's Neurology Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper. Dr. David Coughlin: The main points of this paper in my mind is that α-Synuclein seed amplification assays from cerebrospinal fluid samples is useful in confirming the presence of synuclein pathology in people with clinically suspected dementia with Lewy bodies. But also that, for people who have synuclein positivity, that the presence of Alzheimer's disease mixed pathology is associated with a worse cognitive progression over time. Dr. Greg Cooper: Thank you Dr. Coughlin, for that summary and for all of your work on this topic. Please check out this week's podcast to hear the full interview and read the full article published in Neurology, CSF α-Synuclein Seed Amplification Assays and Alzheimer's Disease Biomarkers in Dementia with Lewy Bodies. Thank you.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this special edition of Mind Moments, Shyam Prabhakaran, MD, MS, the James Nelson and Anna Louise Raymond Professor of Neurology and chair of the Department of Neurology at the University of Chicago Medicine, joined the show to discuss the recent updates to the American Heart Association/American Stroke Association's guideline for the early management of acute ischemic stroke.  Prabhakaran clarified the main takeaways for clinicians and touched on details around endovascular thrombectomy care in pediatrics as well as treatment within and outside of the golden window.For NeurologyLive's coverage of ISC 2026, head here: International Stroke Conference (ISC) To read the new guidelines, head here: 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke AssociationThanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Dr. Greg Cooper talks with Dr. David G. Coughlin about the role of αSyn-SAAs in diagnosing dementia with Lewy bodies and their relationship with Alzheimer disease biomarkers.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

Question Lab: Neuro for Step 1 Think you can spot a subarachnoid hemorrhage from the clues alone? What about localizing a stroke to the exact arterial distribution? In this episode of Question Lab, Dr. Abraham Titus walks through 4 board-style neurology questions, breaking down the clinical clues, teaching the underlying pathophysiology, and walking through the answers step by step. Pause the episode, commit to your answer, then listen to the explanation. It’s the closest thing to a live boards review session you can get on the go. Topics covered: Berry aneurysms and their classic associations Stroke localization and aphasia types Parkinson’s disease pharmacology Traumatic intracranial hemorrhages and herniation syndromes Want to try these Qmax questions yourself? Take the test: https://usmle-rx.scholarrx.com/share/jory9yevdp5kd3g Free Rx Study Planner: https://go.usmle-rx.com/study-schedule Learn more: www.usmle-rx.com

🧭 REBEL Rundown 📌 Key Points The 4 Steps of an ED Consult:👋 Introduce yourself and your role🎯 Lead with the outcome (the ask)🧾 Give a focused case summary (why it’s theirs + what you’ve done)🔁 Close the loop (timeline, next steps, contingencies) Click here for Direct Download of the Podcast. 📝 Introduction Today we’re tackling one of the most important (and most under-taught) skills in emergency medicine: how to call a consult in the ED and what to do when a consultant pushes back.To call a consult in the ED, start with a brief introduction, lead with the outcome you need (“the ask”), give a focused decision-relevant summary, and close the loop with timeline and next steps. If the consultant resists, clarify the “why,” restate the ask, offer alternatives, and escalate when patient safety or disposition is at risk.After two decades in emergency medicine and countless consult calls, here’s a simple framework—plus copy/paste scripts—to make your consults faster, clearer, and easier to say “yes” to. 🤔 Why Consult Skills Matter in Emergency Medicine Consults aren’t a formality—they’re a patient-care intervention. Strong consult communication:Reduces delays in time-sensitive careImproves ED throughput and dispositionDecreases conflict and miscommunicationClarifies ownership and next stepsProtects the patient (and the team) when plans are unclear 🪜 The 4-Step ED Consult Framework (Introduction → Ask → Summary → Close the Loop) Most consult friction comes from one of two problems: unclear expectations or excessive noise. This four-step structure solves both.1) Introduce yourself and your roleA simple intro sets a professional tone and removes ambiguity.Script: “Hey, this is Swami, one of the ED attendings. I’m calling for an ortho consult.” 2) Lead with the outcome (the ask)Don’t bury the lede. The consultant wants to know what you need—immediately.Script: “I’m calling about a patient with a suspected septic knee. I need you to evaluate for operative management.” 3) Give a focused, decision-relevant summaryYour summary should answer:Why this is your service’s problemWhat’s already been doneWhat I’m worried about / what decision is needed nowScript: “43-year-old man with no major PMH, 3 days of knee pain and swelling. XR negative. Febrile. Aspiration yielded purulent fluid—cultures sent. We started antibiotics after the tap. He’s hemodynamically stable.” High-yield pearl: Add quick “stability anchors” when relevant:“Airway stable, pain controlled.”“Neurovascularly intact.”“No signs of compartment syndrome.”“No hypotension or escalating oxygen requirement.” 4) Close the loop (timeline + next steps)This prevents the consult from floating in limbo and protects patient flow.Script: “When do you expect to see the patient, and do you want anything done before you arrive—NPO, repeat labs, additional imaging?” 📝 ED Consult Script General ED Consult Script “Hi, this is Dr. ___ in the ED. I’m calling for a ___ consult. The reason is ___. Briefly: ___ year-old with ___. We’ve done ___ and started ___. I’m concerned about ___. Can you see them today, and what’s your preferred next step?” Septic joint / Ortho Example “Hi, this is Swami in the ED. I need an ortho consult for suspected septic arthritis. 43-year-old with 3 days of atraumatic knee swelling and fever. XR negative. Tap produced purulent fluid—cultures sent. Antibiotics started after aspiration. Can you evaluate for operative management, and when can you see the patient?” Neurology example (time-sensitive) “Hi, this is Dr. ___ in the ED. I need neurology for suspected acute stroke. Last known well ___. NIHSS ___. CT/CTA completed (or pending). I’m calling to discuss candidacy for thrombolysis/thrombectomy and next steps. When can you evaluate and what additional workup do you want now?” ⛓️‍💥 Common ED Consult Mistakes (and Fixes) Mistake: Long story before the askFix: Lead with the outcome in the first sentenceMistake: Unfiltered data dumpFix: Provide only decision-relevant detailsMistake: No timelineFix: Ask explicitly when they’ll see the patient and what they need firstMistake: Implicit “ownership”Fix: Clarify who is admitting, who is following, and what happens if the patient worsens ✋ What to Do When a Consultant Pushes Back Even a perfect consult can meet resistance. Your job is to stay calm, keep it professional, and protect the patient.1) Ask “why?”Don’t argue first—diagnose the refusal.Script: “Help me understand your concern about seeing this patient.” Many refusals are based on misunderstanding: wrong service, missing key detail, or incorrect assumption about stability.2) Restate the consult in one sentence, then offer optionsIf the conversation starts spiraling, reset it.Script: “To be clear, I’m concerned this is septic arthritis and needs ortho evaluation. If you don’t feel you’re the right service, who should be—rheum, medicine, or another surgical team?” This keeps you collaborative while preventing dead ends.3) Humanize the decision (use sparingly)This is a “high-voltage” tool. Use it when stakes are high and you’ve already clarified the medical facts.Script: “I’m worried we’re missing something time-sensitive. If this were your family member, what would you want us to do next?” Use it to re-anchor to patient risk—not as a guilt tactic. ⚡️When and How to Escalate a Consult Escalation isn’t personal—it’s a safety mechanism when there’s an impasse that threatens timely care.When to escalateTime-sensitive condition is delayed (e.g., septic joint, cord compression, testicular torsion, GI bleed with instability)No clear disposition plan despite reasonable ED evaluationConsultant refusal blocks needed specialty decision-makingPatient safety or deterioration risk is increasing in the ED How to escalate (lowest to highest intensity)Ask for the consultant’s attending (if speaking to a resident)Call the on-call attending directlyInvolve ED leadership/medical directorEscalate to service chief/department chair (rare, but real)Hospital supervisor/admin escalation for immediate operational impasseScript: “We’re at an impasse and the patient needs a decision. I’m escalating to clarify ownership and ensure timely care.” ️ Documentation Tips for Consult Refusals Documentation should be factual and patient-centered, not punitive.Include:Your clinical concern and why the consult is neededWho you spoke with (name/role)Their stated reason for refusal or delayAlternatives discussedEscalation steps taken and final plan 👉 FAQ: Emergency Medicine Consults What is the best way to call a consult in the ED?Introduce yourself, lead with the specific ask, summarize only decision-relevant details, and close the loop with a clear plan and timeline.What should I say when a consultant refuses to see a patient?Ask why, clarify misunderstandings, restate your concern and the ask, and request an alternative plan or appropriate service.When should I escalate a consult?Escalate when an impasse delays time-sensitive care, threatens patient safety, or prevents appropriate disposition.How do I document a refused consult?Document the clinical concern, who you spoke with, their stated reason, alternatives discussed, and escalation steps taken. 🏁 Conclusion Mastering emergency medicine consults makes you faster, safer, and easier to work with. The goal isn’t to “win” a consult call—it’s to get the patient the right care, with clear ownership and a shared plan. Post Peer Reviewed By: Marco Propersi, DO (Twitter/X: @Marco_propersi), and Mark Ramzy, DO (X: @MRamzyDO) 👤 Associate Editor Anand Swaminathan MD, MPH All Things REBEL EM Meet The Team 🔎 Your Deep-Dive Starts Here REBEL Core Cast – Pediatric Respiratory Emergencies: Beyond Viral Season Welcome to the Rebel Core Content Blog, where we delve ... Pediatrics Read More REBEL Core Cast 143.0–Ventilators Part 3: Oxygenation & Ventilation — Mastering the Balance on the Ventilator When you take the airway, you take the wheel and ... Thoracic and Respiratory Read More REBEL Core Cast 142.0–Ventilators Part 2: Simplifying Mechanical Ventilation – Most Common Ventilator Modes Mechanical ventilation can feel overwhelming, especially when faced with a ... Thoracic and Respiratory Read More REBEL Core Cast 141.0–Ventilators Part 1: Simplifying Mechanical Ventilation — Types of Breathes For many medical residents, the ICU can feel like stepping ... Thoracic and Respiratory Read More REBEL Core Cast 140.0: The Power and Limitations of Intraosseous Lines in Emergency Medicine The sicker the patient, the more likely an IO line ... Procedures and Skills Read More REBEL Core Cast 139.0: Pneumothorax Decompression On this episode of the Rebel Core Cast, Swami takes ... Procedures and Skills Read More The post REBEL Core Cast 150.0: Emergency Medicine Consults: How to Call a Consult + Handle Pushback (With Scripts) appeared first on REBEL EM - Emergency Medicine Blog.

In part one of this two-part series, Dr. Tesha Monteith and Dr. Andrew Hershey summarize findings from the SPACE trial evaluating fremanezumab in adolescents and children with migraine. Show citation: Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394(3):243-252. doi:10.1056/NEJMoa2504546  Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I'm here with Andrew Hershey, Professor of Pediatrics and Director of the Division of Neurology at Cincinnati Children's and the Children's Headache Center. We're here talking about his new paper published in the New England Journal of Medicine, Fremanezumab in Children and Adolescents with Episodic Migraine. Andrew, thank you for being on our Neurology Minutes. Dr. Andrew Hershey: Thank you for inviting me. Dr. Tesha Monteith: Can you summarize the findings of the space trial investigating Fremanezumab for adolescents and children with migraine? Dr. Andrew Hershey: This is one of the four monoclonal antibodies against CGRP, or it's this receptor that had been proven effective for adults. And it's the first one, the formazepam, that's been able to report its effectiveness in children and adolescents with less than 15 headache days per month. This study looked at over 200 children adolescents that were in a double-blinded randomized placebo controlled study. And reached its primary, as well as its secondary endpoint of a reduction compared to placebo. And the number of attacks of migraine per month, as well as a greater than 50% reduction in the number of headache attacks per month, with minimal to no side effects, the most notable side effect being injection site erythema. Dr. Tesha Monteith: Great. Thank you so much for providing that update. Do check out the full podcast for more details about his paper and the treatment of migraine in children and adolescents. This is Tesha Monteith. Thank you for listening to the Neurology Minute.  

Dr. Birnbaum also addresses common early fears, including confusion about autoimmune disease and anxiety around immunosuppressive medications, reframing treatment as dialing down an overactive immune response rather than taking away your immune system. Throughout the episode, he encourages self-advocacy, realistic hope, and partnership with your care team, and shares insights from his book“Living well with autoimmune diseases”  A Rheumatologist's Guide to Taking Charge of Your Health. The takeaway is empowering and hopeful: we're living in a “golden era” of RA care, with more effective treatments and real reason to believe a full, meaningful life is possible alongside this diagnosis.Episode at a glance:00:20 Dr. Burnbaum's Background and Passion for Arthritis & Neurology05:19 The Diagnostic Process in Rheumatology08:59 Understanding Inflammatory Arthritis15:22 Explaining Autoimmune Diseases and Inflammation23:11 The Role of Immunosuppressive Therapies28:16 Personalized Treatment Plans in Rheumatology30:50 Understanding Diagnostic Criteria and Nuances31:31 Dealing with Diagnostic Ambiguity32:57 Empowerment Through Patient-Doctor Partnership38:10 Practical Tips for Patient Empowerment46:03 Realistic Hope and Coping Strategies56:34 Concluding Thoughts and ResourcesMedical disclaimer: All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Episode SponsorsRheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Yuval Zabar, MD Guest: Michelle Mielke, PhD Guest: Henrik Zetterberg, MD, PhD For the latest insights on tau and neurodegeneration biomarkers in Alzheimer's disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade', the current use of tau and neurodegeneration biomarkers in tracking disease progression, and how the AD biomarker landscape may evolve over time. Doctor Mielke is a Professor of Epidemiology and Neurology at the Wake Forest University School of Medicine, and Professor Zetterberg is a Professor of Neurochemistry at the University of Gothenburg. To learn more about tau in Alzheimer's disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.

Recorded on 12 February 2026 for ICMDA Webinars.Dr Peter Saunders chairs a webinar with Dr Santhosh MathewNeuroscience has progressed rapidly, revealing the brain's capacity for change throughout life. Advances in technology and genetics have enriched our insight, bridging neurology and psychiatry, and emphasising the uniqueness of thought and behaviour.As neuroscience shapes medicine, education and commerce, it raises ethical and societal questions. Understanding the brain's intricacies leads us to consider free will, accountability, and the persistent puzzle of cause and effect, reminding us knowledge remains provisional and growing.For those with faith, these developments inspire humility and awe, acknowledging human knowledge as both privilege and duty.Dr Mathew Santhosh Thomas is an Internal Medicine specialist with experience in academic and rural missional healthcare settings. He has led rural healthcare institutions and HIV care programmes, and served as Executive Director of Emmanuel Hospital Association, a network of 20 hospitals and 40 community programmes in North India. His wife Saira is an Anaesthetist and healthcare administrator; they have two grown-up children and recently relocated to Kerala after 38 years in North India. Passionate about teaching, Dr Mathew Santhosh Thomas focuses on leadership, strategy, and organisational planning. Neurology has been a special area of interest. Presently, he is Training In-Charge at ICMDA (www.icmda.net) and involved in governance of healthcare organisations.⁠⁠⁠⁠⁠⁠⁠⁠To listen live to future ICMDA webinars visit⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://icmda.net/resources/webinars/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

HEALTH NEWS A Simple Diet Change Could Slow Liver Cancer Brief, intensive exercise helps patients with panic disorder more than standard care Lucid dreaming could be used for mental health therapy, new study says US cancer institute studying ivermectin's ‘ability to kill cancer cells Too many saturated fats may be more harmful than too many refined carbohydrates.    Clips   Andrew Bridgen - https://x.com/ABridgen/status/2020573528571977993?s=20 MAHA Alliance Mike Tyson Super Bowl Commercial - https://www.youtube.com/watch?v=jg1SjFt1a_U   KETO DIET RISKS    The rationale for Keto Diet by its advocates Restricting carbohydrates, suppressing insulin and ketosis will lead to better metabolic heath, increase weight loss, reduce inflammation, and protect from chronic diseases.   Keto Claim: Carbohydrates raise insulin leading to fat storage – keto lowers insulin and burns body fat better Debunking: Ketosis is a metabolic state and not a health outcome. For example ketones can be elevated by very long fasting, starvation, different illnesses and uncontrolled diabetes.   Keto Claim: By minimizing carbs keto stabilizes blood sugar, reduce insulin spikes, and improve insulin sensitivity that benefits those with type 2 diabetes Debunked: This claim contradicts the evidence of induced hepatic insulin resistance and glucose intolerance in longer-term studies. In animal models, keto diets impair blood sugar regulation within several days, which shows harm for metabolic health.   Keto Claim: Ketones are seen as “clean” fuel that advocates claim are anti inflammatory and neuroprotective. Believe that this along with ketosis lowers triglycerides, raises HDL cholesterol, and improves lipid profiles. They argue that the increase in LDL cholesterol is benign. Claim saturated fats are harmless if carbs are low Debunked:  This claim is undermined by the increased LDL cholesterol, triglycerides, and cardiovascular risks from saturated fats in animal products. Meta-analyses show no long-term lipid improvements from keto diets. Rather this is the risk in elevated low-density lipoprotein and very-low-density lipoproteins that increase cardiovascular disease  Also, insulin reduction does not override the quality of fat. LDL cholesterol and ApoB, as well as atherosclerosis, increase significantly on an animal based diet. Saturated fat still remains a causal factor for cardiovascular disease.   Keto Claim: High protein and fat increases satiety and therefore reduces hunger Debunking: Weight loss is primarily from reduced intake due to satiety, not fat-burning efficiency. Long-term keto adherence often leads to weight regain with no significant sustained benefits for visceral fat or appetite control. hort term weight loss is not same as long term benefits. A study shows that weight loss at 3-6 months on a keto diet disappears by 12 months   Keto Claim: It enhances brain function and energy that then improves mental clarity and mood. Argue that animal products like eggs and organ meats provides choline and other nutrients for brain health. Debunked: There is no strong evidence for this claim. In fact keto's nutrient deficiencies and lack of fiber in the long term can lead to fatigue, constipation and in women neural tubal defects. Keto's claims are only based on short term trials.    Keto Claim: Use the evolutionary argument that humans evolved eating meat and fat – same argument the paleo folks used. Therefore, they believe keto diets align with human biology Debunked: A big study in Science in 2025 analyzed tooth enamel from skeletons of some of our oldest human ancestors, 3.5 million years ago, and found they ate predominately a plant based diet with no substantial sigh of mammalian meat. The isotopes matched herbivores (fruits, leaves and grasses, tubers, nuts, other vegetation) not carnivores.     Keto Diet Risks   It is worth noting, according to the Northwestern University Health site, there is a sizable drop out rate of participants in keto trials.   Although, there are studies that show keto does what it claims in the short term, there are no long-term human data to support their claims that an animal-based diet does this efficiently.   Important, research leans in the direction to indicate that keto's benefits – especially weight loss and glucose reduction, are transient and may not be directly related to animal food consumption itself but rather to calorie reduction and limiting glycogen.   Long term prospective studies and systematic meta analysis evaluations consistently show high red meat consumption, full-fat dairy and animal fats are associated with the following medical conditions. This is true even when carbohydrate intake is low   A good thorough study in JAMA shows that unprocessed red meat mildly increases all cause mortality – about 3-5% per 100 grams meat per day   High red and processed meat consumption increases carcinogenic N-nitroso compounds and heterocyclic amines that raise cancer risks by up to 18% per 50-100 grams/day – from meta analysis in the European Journal of Epidemiology   Dairy increases IGF-1 levels thereby too much calcium also suppressing Vitamin D and elevating prostate cancer risks by 79% per 400 gram dairy per day. Worse for processed meats that inreases risk by 21% per 20 grams/day – American Journal of Epidemiology   Red meat is linked to hormonal disruptions and carcinogens contributing breast cancer – European Journal of Cancer   Total unprocessed red meat consumption shows a modest 5% risk in pancreatic cancer per 100 grams/day. – From journal Clinical Nutrition   Many meta-analyses on meats have a relationship to stomach/gastric cancer, but processed meats are worse than unprocessed red meat. From study in Nutrients – 24 studies showed unprocessed red meat associated with gastric cancer by about 25% increase risk for every 100 grams/day.   Unprocessed red meat is linked to an 11% higher risk in overall cardiovascular disease risk due to inflammation and endothelial dysfunction. – from European Heart Journal   Saturated fats in meats increases non-HDL cholesterol and blood pressure and raises the risks of ischemic heart disease by 119% per 100 grams/day red meat – from American J Clinical Nutrition   Red meat diets reduce LDL Cholesterol much less than plant proteins and thereby increase atherosclerosis risks – from the journal Circulation   Red meats (an processed meats also in this study) contributes to insulin resistance via heme iron and raises Type 2 diabetes risks by up to 51% per 50 grams/day – International Journal Environmental Research in Public Health   Saturated fats in unprocessed red meat has a modest positive 12% increase with stroke risk – From  European Heart Journal Unprocessed poultry consumption shows a modest 4% increase in incident cardiovascular events per 100 grams/day. This is believed to be due to arachidonic acid poultry – in JAMA   Red meat contributes to sodium and saturated fat intact raising hypertension conditions by 14% per 50-100 gram/day – from journal Advanced Nutrition   Saturated fats from animal products cause lipotoxicity and insulin resistance, that promotes hepatic fat accumulation leading to non-alcoholic fatty liver disease – from Cardiovascular Development and Disease   High animal protein increases urinary calcium and acid overload leading to the formation of kidney stones – from the journal Nutrient   Animal-heavy diets have low fiber and micronutrient intake that contribute to nutrient deficiencies. Also causes constipation that can lead to immune system issues. – from the journal Nutrients   Red meat, dairy, and eggs disrupts the gut metabolism of carnitine and choline. This promotes TMAO plaque formation and inflammation that leads to atherosclerosis. – from Journal of Cardiovascular Development.   Although unprocessed meat consumption has not been adequately associated with dementia and Alzheimer's – yes, processed meats do – there are studies showing red meat is associated with “subjective cognitive decline” (SCD) which is related to precursors to dementia and Alzheimer's. A study in journal Neurology  links unprocessed red meat eaten at 1 or more servings per day to 16% higher risk in SCD.   High caloric density from saturated animal fats displaces fiber that contributes to weight gain obesity. From Neal Barnard in the American Journal of Clinical Nutrition   Animal products transmit prions that are associated with neurodegenerative disorders.  Proinflammatory compounds like TMAO are linked to neurological risks. – in International Journal of Molecular Science

Send a textDr. Angela Stanton is a beloved returning guest on our show! Be sure to check out her first appearances on episode 70 and on episode 288 of Boundless Body Radio, both of which are some of our most downloaded and talked about episodes of all-time!Dr. Angela Stanton is a neuro-economist who evaluates changes in human behavior, including chronic pain, decision making, and hormonal variations in the brain. Her current research is focused on migraine cause, prevention and treatment without the use of medicines, and her discovery was helped by experimenting on herself.As a long-term sufferer of migraines herself, Dr. Stanton has dedicated her life to finding their root cause and developed the Stanton Migraine Protocol. She has written many books, including Fighting the Migraine Epidemic: Complete Guide: How to Treat and Prevent Migraines Without Medicines, a comprehensive body of work on migraine prevention and treatment without taking any medicines.Her book is a self-help guide with a full explanation about how to successfully abort and prevent all migraines. The book also provides a full explanation of the cause of migraines from a physiological, biological, and genetics perspective. She currently lives in Southern California.Find Dr. Stanton at-https://stantonmigraineprotocol.com/migraine-book.comNon-Profit- https://www.stantonmigraineprotocol.org/FB Group- Stanton Migraine ProtocolFB- Angela A. Stanton, Ph.D.IG- @drangelastantonTW- @MigraineBookFind Boundless Body at- myboundlessbody.com Book a session with us here!

This episode covers craniosynostosis.Written notes can be found at https://zerotofinals.com/paediatrics/neurology/craniosynostosis/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Many serious medical illnesses are associated with some degree of serum electrolyte abnormality, renal impairment, or both. The neurologist must determine if the patient's neurologic symptoms are related to the renal and electrolyte disturbances or whether a concurrent primary neurologic process is at play. In this episode, Casey Albin, MD, speaks with Eelco F. M. Wijdicks, MD, PhD, FAAN, FACP, FNCS, author of the article "Neurologic Manifestations of Renal and Electrolyte Disorders" in the Continuum® February 2026 Neurology of Systemic Disease issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Wijdicks is a professor of neurology and attending neurointensivist for the Neurosciences Intensive Care Unit at Mayo Clinic in Rochester, Minnesota. Additional Resources Read the article: Neurologic Manifestations of Renal and Electrolyte Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Guest: @EWijdicks Full episode transcript available here

Those who hope to honor God and advance Jesus' Kingdom face powerful opposition from spiritual, physical, and psychological enemies. Successful launching and long term fruitfulness depends on recognizing and, in dependence on the Holy Spirit, waging war against those enemies.

This week, we're joined by Dr. Lauren Kenworthy, a leading expert in the field of autism and executive functioning. Dr. Kenworthy is the author of Unstuck and On Target, a school-based intervention program proven to help children on the autism spectrum develop critical executive functioning skills. Today we will be discussing how executive functioning impacts learning and daily life for autistic individuals, as well as practical strategies to support these skills at home, in school, and beyond. Download latest episode!  Resources Lauren Kenworthy, Ph.D.  Pediatric Neuropsychologist Chief, Division of Pediatric Neuropsychology Children's National (Washington DC) Professor, Pediatrics, Neurology, Psychiatry George Washington University Medical School Research Website: https://www.childrensnationalcasd.com ............................................................... Autism weekly is now found on all of the major listening apps including apple podcasts, stitcher, Spotify, amazon music, and more. Subscribe to be notified when we post a new podcast. Autism weekly is produced by ABS Kids. ABS Kids is proud to provide diagnostic assessments and ABA therapy to children with developmental delays like Autism Spectrum Disorder. You can learn more about ABS Kids and the Autism Weekly podcast by visiting abskids.com.

Human pluripotent stem cells (hPSCs) are transforming the study of biology and disease by enabling scientists to grow large amounts of specific cell types in the lab that were once difficult to obtain. Our guests today focus on improving the derivation and study of sensory neurons, which are sparse and diverse nerve cells near the spine that carry information like pain, touch, or position of the body to the brain. Damage to these neurons or sensory neuropathies, as can happen in diabetes or infections, is estimated to affect millions of people worldwide, yet treatments are limited. To improve the generation of human sensory neurons, the authors developed a genetic toolkit to fluorescently label these individual cells and their subtypes. This approach enables more precise study of these subtypes, their roles in disease, and potentially the development of treatments for sensory neuropathies. GuestsJoriene C. de Nooij, PhD, Department of Neurology, Columbia University, USA Eti Malka-Gibor, PhD, Department of Neurology, Columbia University, USA HostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationSupporting ContentPaper link: Derivation and analysis of human somatic sensory neuron subtypes facilitated through fluorescent hPSC reporters," Stem Cell ReportsAbout Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. X: @StemCellReportsAbout ISSCRAcross more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to advancing stem cell research and its translation to medicine.ISSCR StaffKeith Alm, Chief Executive OfficerShuangshuang Du, Scientific Programs ManagerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsMegan Koch, Senior Marketing ManagerJack Mosher, Scientific DirectorHunter Reed, Senior Marketing Coordinator 

Many patients will affirm seeing clouds shaped like animals or other similar phenomena, which is why confirming pareidolia (seeing meaningful images in meaningless visual stimuli) is such a tricky symptom in dementia with Lewy bodies (DLB). While it may not be exclusive to DLB, placing such symptoms in the context of "the company it keeps" is a key method to narrowing down the diagnosis. The Editors' Choice paper for the February 2026 issue of Practical Neurology is a practical guide to the clinical diagnosis and management of DLB. Authors Dr. Sarah Fullam¹ ² and Dr. Seán O'Dowd¹ ³ join PN podcast editor Dr. Amy Ross Russell to discuss their work. They describe the importance of the initial examination, from the patient's gait to difficulties in word retrieval. They also touch on challenges in the use of biomarkers, which drugs may be helpful, and how to advise patients and their carers. Read the paper: Dementia with Lewy bodies: a practical guide to clinical diagnosis and management Special thanks to The Podcast Studios Dublin for their assistance with the recording of this episode. (1) Tallaght Institute of Memory and Cognition, Tallaght University Hospital, Dublin, Ireland (2) Trinity College Dublin School of Medicine, Dublin, Ireland (3) Trinity College Dublin Academic Unit of Neurology, Dublin, Ireland Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest episodes. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. This episode was hosted by PN's podcast editor Dr. Amy Ross Russell. Production by Amy Ross Russell and  Brian O'Toole. Editing by Brian O'Toole. Thank you for listening.

Dr. Tesha Monteith talks with Dr. Andrew D. Hershey about the advancements in the treatment of pediatric migraines.  Read the related article in The New England Journal of Medicine.  Disclosures can be found at Neurology.org. 

This episode covers hydrocephalus, particularly in children.Written notes can be found at https://zerotofinals.com/paediatrics/neurology/hydrocephalus/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Welcome to another episode of the Sustainable Clinical Medicine Podcast! In this episode, our host welcomes Dr. Andrew Wilner to discuss his extensive career in medicine, detailing his certifications in internal medicine, neurology, and epilepsy. Dr. Wilner shares his multifaceted journey, from starting as an ER doctor without formal training to becoming a professor of neurology. He delves into the evolution of the internship model and offers advice for medical students in career decision-making. Dr. Wilner also elaborates on the locum tenens lifestyle, discussing the challenges and benefits, including the necessary preparation and mindset for success. Additionally, he highlights his experiences in academic roles, private practice, and as a medical journalist. The conversation concludes with insights into Dr. Wilner's book, 'The Locum Life: A Physician's Guide to Locum Tenens,' and his podcast, 'The Art of Medicine,' featuring stories of physicians pursuing unique medical careers. Here are 3 key takeaways from this episode: Flexibility is Essential for Locums Success: Locums work requires adaptability in every aspect - assignments can be canceled last minute, you'll work in unfamiliar systems, and conditions are often less than ideal. The ability to be flexible and resourceful is more important than clinical skills alone. Prepare Thoroughly Before Each Assignment: Arrive 2 days early to handle logistics: learn the EMR system (demand paid training), scout parking and accommodations, get credentialing done, and eliminate uncertainties. This preparation reduces stress and lets you focus on patient care when the assignment starts. Locums Prevents Burnout and Maintains Career Options: Working locums (even part-time) keeps you clinically active, resets credentialing clocks, and provides control over your schedule. Many burned-out physicians rediscover their love of medicine through locums by working on their own terms (7-9 months/year) rather than leaving clinical practice entirely. Meet Dr. Andrew Wilner: Dr. Wilner has worked locum tenens on and off since 1982 and is the author of "The Locum Life: A Physician's Guide to Locum Tenens." Dr. Wilner is Professor of Neurology at the University of Tennessee Health Science Center in Memphis, Tennessee, and host and producer of the Art of Medicine with Dr. Andrew Wilner podcast since 2020. Dr. Wilner is a PADI Divemaster and passionate underwater photographer. Connect with Dr. Andrew Wilner:

Katlyn Nemani, MD, explores how autoimmune and inflammatory brain disorders can present as first-episode psychosis—and why some patients diagnosed with schizophrenia may actually have a treatable immune-mediated illness. She explains the clinical features that should prompt suspicion for autoimmune psychosis, including subacute onset, subtle neurologic signs, and poor response to antipsychotics, even when standard imaging and antibody tests are unrevealing.Dr. Nemani also discusses the limits of current biomarkers, how to think clinically when diagnostic certainty is incomplete, and why early immunotherapy can dramatically alter outcomes. The conversation closes with a forward-looking discussion of emerging research suggesting that a meaningful subset of schizophrenia-like illness may ultimately be reclassified as autoimmune in origin.Katlyn Nemani, MD, is a Research Assistant Professor in the Departments of Psychiatry and Neurology at NYU Grossman School of Medicine and a graduate of NYU's combined Neurology-Psychiatry residency program.▶️ Watch Insights on Psychiatry on YouTube00:00 When Psychosis May Be an Autoimmune Disease01:18 Early Psychiatric Symptoms of Autoimmune Encephalitis02:47 Why Subtle Neurologic Clues Matter04:00 A Case of Rapidly Reversible Psychosis06:37 The Limits of Antibody Testing07:51 Why Early Treatment Changes Outcomes08:18 Rethinking the Heterogeneity of Schizophrenia09:31 How Common Is Autoimmune Contribution to Psychosis?10:48 Network-Level Brain Effects and Open Research QuestionsThis episode is intended for psychiatrists, neurologists, and other clinicians interested in psychosis, neuroinflammation, and complex diagnostic presentations at the psychiatry–neurology interface.This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

This episode features Chris Breitigan reading 3 neurology questions from our online qbank. Dr. Ted O'Connell Ted O'Connell, MD, FAAFP, is the Director of Medical Education for Kaiser Permanente Northern California. He is also an Associate Clinical Professor in the Department of Family and Community Medicine at the UC San Francisco School of Medicine.  Ted has authored over 20 medical textbooks, edited 10 additional textbooks, and has written over 900 textbook chapters as well as articles in peer-reviewed medical journals. Ted has been involved in medical education for over two decades, serving as Founding Program Director at the Kaiser Permanente Napa-Solano family medicine residency program for 10 years and the Program Director at the Kaiser Permanente Woodland Hills residency program for 7 years. Ted is Editor-In-Chief of Elsevier's Clinical Key Student, an international medical education platform. Ted is also the award-winning host of several podcasts.  Dr. Raj Dasgupta Dr. Raj is a quadruple board-certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. Our Websites ⁠⁠⁠MedPrepToGo Website⁠⁠⁠ ⁠⁠⁠BookRevision.com⁠⁠⁠ ⁠⁠⁠Dr. O'Connell's Website⁠⁠⁠ ⁠⁠⁠Dr. Dasgupta's Website⁠⁠⁠ Other Podcasts ⁠⁠⁠USMLE Step 1 Questions⁠⁠⁠ ⁠⁠⁠USMLE Step 1 Ad-Free Bundle⁠⁠⁠ ⁠⁠⁠Crush Step 1⁠⁠⁠ ⁠⁠⁠Step 2 Secrets⁠⁠⁠ ⁠⁠⁠Beyond the Pearls⁠⁠⁠ ⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠ ⁠⁠⁠Beyond the Pearls Premium⁠⁠⁠ ⁠⁠⁠USMLE Step 3 Review⁠⁠⁠ Legal/Credits All information is for entertainment and educational purposes only and is not intended as medical advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pre-Order my new book ADHD IS OVER! now on Amazon: tinyurl.com/532b2ck8 This episode is part 3 of a collaboration with Psychiatrist Dr. Ethan Short. Dr. Short is board-certified by the American Board of Psychiatry and Neurology and he has extensive experience working with adults with severe mental illness including schizophrenia, bipolar disorders, addictions, PTSD, depression, anxiety disorders, and adult ADHD. He has dedicated over 500 hours to educating medical students, residents, social workers, nursing staff, as well as volunteering his time to local high schools and guidance counselors to help educate the public on mental health needs. Dr. Short is also the host of the “Renegade Psych” podcast, committed to returning medicine's focus to PROGRESS OVER PROFIT, and limiting the influence and power of the pharmaceutical industry and big business entities, whose primary motivations are financial in nature. Here is part 3 of our in-depth conversation on ADHD, mental health and the importance of questioning the main stream medical narrative and using our common sense. For more information on Dr. Ethan Short and the Renegade Psych Podcast, please visit https://renegade-psych.beam.ly For more information on this podcast, please visit www.adhdisover.com

This episode covers squint.Written notes can be found at https://zerotofinals.com/paediatrics/neurology/squint/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

In part one of this series, Dr. Justin Abbatemarco explores how to effectively reach today's learners through podcasts and social media. Show transcript: Dr. Justin Abbatemarco: Hello and welcome. This is Justin Abbatemarco, and I just got done finishing an episode on non-traditional educational formats reshaping neurology training. I was joined by some really terrific teachers and faculty members, Roy Strowd, Jeff Ratliff and Tesha Monteith, and it was really great hearing from these different perspectives. On today's Neurology Minute, we really want to talk about how we can reach our learners in today's learning environment, and I think two themes emerged from our conversations, especially around podcasts and social media. You know, the example I always think about is when we get done learning in either the bedside or clinic rounding, and I try to share some articles with our learners, I find that if I send a bunch of PDFs or textbook chapters, it just doesn't resonate as well these days. And so trying to reach learners where they're at, and I think podcasts and social media feeds allow for this kind of asynchronous, really engaging learning style. It allows for them to listen at a time that's convenient for them, to get the information in a different way in some audio or audiovisual type ways, and to hear from experts around the world that maybe have a different voice and can resonate the message in a different way, which I find really powerful. I think the other part of this is that those social media feeds allow for a sense of community that is hard to replicate in a traditional classroom, and the ability for them to, again, listen to an expert in a less intimidating circumstance or a setting, and then to hear from other learners on questions they've had really resonates with folks. I would really encourage everyone to listen to the entire interview with the entire team. It was, again, great to hear from all the different experts on this topic, and I appreciate your time, and that's today's Neurology Minute.

Dr. Evan Noch interviews Dr. Lisa DeAngelis about her career in neuro-oncology, role as Chair of Neurology and Physician-in-Chief at Memorial Sloan Kettering Cancer Center, and advice for trainees entering the field.

All Home Care Matters and our host, Lance A. Slatton were honored to host and celebrate the retirement of Dr. James Vickers.   About Dr. James Vickers:   Distinguished Professor Dr. Vickers has an extensive track record in interventional cohort studies, cognition, neurogenetics, health services research and neuroscience research, and has published over 200 refereed articles. Distinguished Prof Vickers has held several national leadership roles, such as President of the Australasian Neuroscience Society (ANS, 2014–2016) and Chair of the Scientific Panel of the Alzheimer's Australia Dementia Research Foundation (2014-2016).   He was awarded a Doctor of Science from University of Tasmania in 2005 in recognition of his contribution to neuroscience research. He is a Board Member of the Dementia Australia Research Foundation and a member of the Dementia Expert Reference Group for the Australian Government Department of Health, Disability and Ageing.    Dr. James Vickers officially announced his retirement as Director of the Wicking Dementia Research & Education Centre at the University of Tasmania (UTAS) at the end of December 2025.   The distinguished panel that joined in celebrating Dr. Vickers career and contributions to field of dementia included:   Bettina Morrow - Associate Director Adult Protective Services   Dr. Jane Alty - Professor of Neurology at University of Tasmania Staff Specialist in Neurology at Royal Hobart Hospital   Henry Brodaty - Scientia Professor Co-Director, Centre for Healthy Brain Ageing UNSW   Agnieszka Chudecka - PICAC Alliance Secretariat Lead (Partners in Culturally Appropriate Care)   Tim England - Podcaster and Dementia Care Expert/Educator who De-mystifies and De-stigmatises Dementia.   Amy Sender - Dementia Consultant at Montefiore   Graeme Samuel AC - Professor. Chair Dementia Australia Research Foundation   Joanna Sun - Lecturer   Kate Lawler - Associate Professor, Physiotherapy La Trobe University, Australia   Dr. Kathleen Doherty - Senior Lecturer in Dementia at the Wicking Dementia Research and education Centre and program lead for Equip and DREAM- two federally funded projects aiming to improve the knowledge and understanding of the aged care workforce   Matt Kirkcaldie - Senior lecturer at University of Tasmania   Sarah-Kaye Page - Trainer and Assessor, The Gordon TAFE   Tanya Buchanan - Professor and CEO of Dementia Australia   With a special video from Alzheimer's Disease International.

In this special episode, Dr. Roy Strowd talks with Drs. Jeff Ratliff, Tesha Monteith, and Justin Abbatemarco about non-traditional educational formats and how they're reshaping neurology training.  Disclosures can be found at Neurology.org. 

Pre-Order my new book ADHD IS OVER! now on Amazon: tinyurl.com/532b2ck8 This episode is part 2 of a collaboration with Psychiatrist Dr. Ethan Short. Dr. Short is board-certified by the American Board of Psychiatry and Neurology and he has extensive experience working with adults with severe mental illness including schizophrenia, bipolar disorders, addictions, PTSD, depression, anxiety disorders, and adult ADHD. He has dedicated over 500 hours to educating medical students, residents, social workers, nursing staff, as well as volunteering his time to local high schools and guidance counselors to help educate the public on mental health needs. Dr. Short is also the host of the “Renegade Psych” podcast, committed to returning medicine's focus to PROGRESS OVER PROFIT, and limiting the influence and power of the pharmaceutical industry and big business entities, whose primary motivations are financial in nature. Here is part 2 of our in-depth conversation on ADHD, mental health and the importance of questioning the main stream medical narrative and using our common sense. For more information on Dr. Ethan Short and the "Renegade Psych" podcast, please visit https://renegade-psych.beam.ly For more information on this podcast, please visit www.adhdisover.com

This episode covers cerebral palsy.Written notes can be found at https://zerotofinals.com/paediatrics/neurology/cerebralpalsy/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Dr. Aaron Zelikovich discusses recent survey findings highlighting the wide variability in how clinicians evaluate and diagnose small fiber neuropathy. Fill out the Neurology® Clinical Practice Current survey.  Show citation:  Thawani S, Chan M, Ostendorf T, et al. How Well do We Evaluate Small Fiber Neuropathy?: A Survey of American Academy of Neurology Members. J Clin Neuromuscul Dis. 2025;26(4):184-195. Published 2025 Jun 2. doi:10.1097/CND.0000000000000502  Show transcript:  Dr. Aaron Zelikovich: Welcome to today's Neurology Minute. My name is Aaron Zelikovich, a neuromuscular specialist at Lenox Hill Hospital in New York City. Today, we will discuss a recent article, How Well Do We Evaluate Small Fiber Neuropathy? A survey of The American Academy of Neurology members, which evaluates small fiber neuropathy in clinical practice. The current landscape of evaluating and testing for small fiber neuropathy remains highly variable in regards to serum testing, skin biopsy, and nerve conduction studies. In this survey study, 800 members of The American Academy of Neurology were randomly selected and emailed a survey. 400 neuromuscular physicians and 400 non-neuromuscular physicians were selected. The overall response rate was 30% with half of the completed surveys coming from neuromuscular physicians. The most common overall initial blood work for this patient population was a CBC, vitamin B12, basic metabolic profile, TSH, and hemoglobin A1C. Other high yield blood tests included ESR, SPEP, immunofixation, and ANA. 70% of responders would also order a nerve conduction study as part of the initial workup. Second line evaluation had less consensus and included skin biopsies for intraepidermal nerve fiber density, hepatitis panel, HIV, and paraneoplastic testing. Responders noted that if the patient had acute onset of symptoms, had symptoms that were asymmetric, or being under 30 years old, they would order a more extensive workup. The authors discussed the importance of both clinical exam, history, and diagnostic workup in patients with symptoms compatible with small fiber neuropathy. They highlight that there is no current objective gold standard for a diagnosis of small fiber neuropathy. The current diagnostic recommendation by the AAN for distal symmetric polyneuropathy includes serum blood sampling for glucose, vitamin B12, SPEP, and immunofixation. Clinical practice in the diagnosis of small fiber neuropathy remains highly variable based on the provider and clinical context of the patient. Neurology Practice Current is currently accepting surveys on clinical practice patterns for patients with small fiber neuropathy. Please check out the link in today's Neurology Minute to complete the survey. Thank you and have a wonderful day. 

Neurologist Dr. Vinit Banga explains stress, sleep, stroke symptoms, brain health, and the effects of pollution on the brain in this powerful podcast episode with Gaurav Arora.This episode covers:•Stress symptoms and how chronic stress damages the brain•Deep sleep and why sleep is essential for brain repair•Stroke warning signs (FAST symptoms) and why minutes matter•Brain fog, memory loss, cognitive decline, early dementia signs•Delhi pollution / AQI effects on brain ageing and intelligence•Migraine triggers, headaches, and dangerous neurological red flags•Doctor-patient trust, Practo ratings, healthcare commercialization in India00:00 Impact of Delhi's Pollution on Brain Health00:37 Stress and Its Effects on Health01:39 Air Quality and Brain Aging03:24 Blood-Brain Barrier and Pollution06:03 Memory Issues and Aging07:04 Understanding Memory Formation12:20 Sleep Disorders and Brain Health13:35 The Importance of Deep Sleep16:09 Stress: The Silent Disruptor46:38 Doctor-Patient Trust and Ethical Concerns55:14 Commercialization in Healthcare01:04:15 Concluding Thoughts and GratitudeDr. Vinit Banga is Director & Head of Neurology & Neurovascular Intervention at Fortis Escorts, and shares life-saving insights on preventing stroke, protecting brain function, and understanding modern neurological risk factors.Keywords: neurologist podcast, brain health India, stress and stroke, sleep and brain, stroke symptoms, stroke warning signs, Delhi pollution brain damage, brain fog, dementia signs, migraine, Fortis neurologist, Dr Vinit Banga, Gaurav Arora podcast.#Stress #Stroke #BrainHealth #Sleep #Neurology #Podcast #DrVinitBanga

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Aaron L. Berkowitz, MD, PhD, FAAN, who served as the guest editor of the February 2026 Neurology of Systemic Disease issue. They provide a preview of the issue, which publishes on February 2, 2026. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @AaronLBerkowitz Full episode transcript available here Dr Jones: The human nervous system is so complex. You can spend your whole career studying it and still have plenty to learn. But the human brain does not exist in isolation. It's intricately connected with and reliant on other bodily systems. When those systems go awry, sometimes the first sign is in the nervous system. Today we will speak with Dr Aaron Berkowitz, an expert on the neurology of systemic disease, and learn a little about how these disorders can present and what we can do about it. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Aaron Berkowitz, who is Continuum's guest editor for our latest issue of Continuum on the neurology of systemic disease. Dr Berkowitz is a professor of clinical neurology at the University of California, San Francisco, and he has an active practice as a neurohospitalist and in outpatient general neurology---and, importantly, as a clinician educator. In addition to numerous teaching awards, Dr Berkowitz has published several books and also serves on our editorial board for Continuum. Dr Berkowitz, welcome. Thank you for joining us. Why don't you introduce yourself to our listeners?  Dr Berkowitz: Thanks, Lyell. As you mentioned, I'm a general neurologist and neurohospitalist here in San Francisco, California at UCSF and very involved in resident education as well. And I was honored, flattered and a little bit frightened when I received the invitation to guest edit this massive issue on the neurology of systemic disease. But I've learned a ton, and it's been great to work with you and the incredible authors we recruited to write for us. And I'm excited to have the issue out in the world.  Dr Jones: Yeah, me too. And you and I have talked about it before: you're one of a very small group of people who have guest edited multiple issues on different topics, right?  Dr Berkowitz: That's right. I did the neuroinfectious disease issue in… was it 2020? 2021? Something like that.  Dr Jones: Yeah. So, congratulations, more people have walked on the moon than done what you've done. And I'm looking forward to chatting, Aaron, and really grateful for your work putting together a fantastic issue. I think our listeners will appreciate that the nervous system does not function in isolation. It's important to understand the neurologic manifestations of diseases that originate within the brain, spinal cord, nerves, muscles, etc., but also the manifestations of diseases that begin in other systems and, you know, may masquerade as a primary neurologic disorder. So, it's obviously an important topic for neurologists, since many of these patients are receiving care in another setting, perhaps from another specialist. I almost think of this issue of Continuum as a handbook for the consultant neurologist, inpatient or outpatient. I don't know. Do you think that's a fair characterization of the topic? Dr Berkowitz: Absolutely. I completely agree with you. I think, yeah, many of us go into neurology interested in our primary diseases, whether it's stroke or Parkinson's or neuropathy or particular interest in neurologic symptoms, whether they're cognitive, motor, sensory, visual. And we quickly learn in residency, right? As you said, a lot of what we see is neurologic manifestations of primary diseases. So, I don't know how similar this is to other training programs. But it seemed like, if I'm remembering correctly, my first year of residency was mostly on primary neurology services, general stroke, ICU. And we moved into the consultant role more in the PGY-3 year the next year. And I remember explaining to students rotating with us on the consult services, this is actually much more complex in a way, because the patient has some type of symptom in a much broader and much more complicated context of multiple things going on. And I call it "neurology in the wild." There's, like, neurology of, this patient's had a stroke and we know they have a stroke and we're trying to figure out why and treat it. That's all interesting. But our question here, is there a stroke needle buried in this haystack of all of these medical or surgical complications? And learning what I call neurology of X, which is really what this issue is; as you said, that there's a neurology of everything. There's a neurology of cardiac disease. There's a neurology of the peripartum. There's a neurology of rheumatologic disease. There's every new treatment that comes out in oncology has a neurology we learn, right? There's a neurology of everything.  Dr Jones: There's a lot of axes, right? There's the heart-brain axis and the kidney-brain axis. And… I think we cover everything except the spleen-brain axis, which maybe that's a thing, maybe not. I'll probably hear from all the spleen fans out there. So, I want to do a little bit of an experiment. We're going to do something new today on the podcast. Before we get into the questions, we're going to start with a Continuum Audio trivia question. So, this will be a first time ever. Dr Berkowitz, we all know that chronic hyperglycemia, or diabetes, can lead to many neurologic and systemic complications and that optimal glucose control is our goal. For our listeners, here's the question: what neurologic complication can occur from correcting hyperglycemia too quickly? What neurologic complication can occur from correcting hyperglycemia too quickly? Stick around to the end of our interview for the answer. So, Aaron, let's get right to it. You had a chance to review all the articles in this issue on the neurology of systemic disease. What do you think in all of those is the most exciting recent development for patients who fit into this category? Dr Berkowitz: Yeah, that's a great question. I think we talked about when we were putting this issue together, right, a lot of the Continuum subspecialty topics; there should have been updates on particular disease diagnostics, treatments, new phenotypes. Whereas here probably a lot less has changed in primary heart disease, primary cancer. As I'd like to say to our students trying to excite them about neurology, most specialties have new treatments, but I can name a large number of new diseases, right, that have been discovered since we've been out of training. So, a lot of the primary medicine stays the same, and the neurologic complications stay the same. But probably the thing that many readers will want to keep handy and will probably be much in need of update again in three years are the neurologic complications of all the new cancer treatments. So, if we think back to I finished training just over ten years ago when a lot of the fill-in-the-blank-umabs were coming out, CAR T therapy, and we were starting to see a lot of neurology, I remember, related to these and telling the oncologists and they said, oh, you just wait. We are seeing at the conferences that there's a lot of neurology to these. And I feel like that is always a moving target. And I think we are seeing a lot of those and it's hard to keep up with which treatments can cause which complications, which syndromes and which severities require holding the treatment when you can rechallenge longer-term complications of CAR T cell therapies now that we've learned more about the acute complications. So, Amy Pruitt from Penn has written us a fantastic article for this issue that covers a lot of the updates there. And I learned a lot from that. I feel like that's the one that just like every time the carnioplastic diseases are reviewed in Continuum, it seems like the table is another page longer from your colleagues there in Rochester teaching us about new antibodies. And I feel like, for this issue, that's one of the areas that felt like there was a lot of very new content to keep up with since last time.  Dr Jones: That's good news, right? It's good that we have new immunotherapies for cancer, but it does lead to neurologic catastrophes sometimes, and it is a moving target, really rapid. So, you mentioned that just over ten years ago you finished your training and now we see a lot more of these complex immunotherapy-related neurologic complications. What about in the other direction? Are there any things that you see less commonly now in your practice than you might have seen ten years ago right when you were finishing training?  Dr Berkowitz: I would say no, I think. I think we're seeing a lot of new stuff, and we're still seeing a high volume of the classic consults we tend to get, whether that's altered mental status in a patient who's systemically ill; weakness or difficulty reading from the ventilator in a patient who's critically ill; patient has endocarditis and has a stroke hemorrhage or mycotic aneurysm, what do we do? Yeah, one of the parts that was really fun and educational editing this issue is, I really wanted to ask the experts the questions I find that are really troubling and challenging and make sure we could understand their perspective on things like the endocarditis consult, which I always feel like each time there's some twist that even though the question is what do we do about this stroke and/or hemorrhage and/or aneurysm and is surgery safe? It seems like each time I always feel like I'm reinventing the wheel, trying to really sort out how to think about this. And we have a great article from Alvin Doss at Beth Israel and Steve Feskey from Boston Medical Center. It covers a lot of cardiology, as you know, in that article about a great section on endocarditis where every time it came back for review, I would say, but what about this? This comes up. What about this? Can you explain how you think about this for our readers? I don't know. I'd be curious to hear your perspective. It sounds like we agree on what has become more common. I don't think anything in neurology seems to become less… Dr Jones: Well, no, I guess we haven't really solved anything, I guess we haven't cured any problem. But that's okay, right? I mean, it's building on an established foundation of experience and history in our field. And you know, we mentioned earlier that in many ways this issue is kind of like a neurology consultant's handbook. We did something a little different with it in that sense. In addition to you serving as the guest editor, you have authored an article in the issue. It touches on something that we've talked about a couple of times, and I'd be interested to hear you talk through it with our listeners a little bit on how to approach the neurologic consultation. Tell us a little more about that and your article and how you approached it.  Dr Berkowitz: Oh, yeah, thanks. Well, thanks first of all for inviting me to think about a sort of introductory article to this issue. And I was trying to think about what to write about because, as you've said and we've been talking about, no one could know every neurologic complication of every medical disease, treatment, surgery, hospital context. Probably many of us don't even know all the muscle diseases, right, within neurology. So how could we know all this stuff? And we need some type of manual from our colleagues that can explain, okay, I know this patient has inflammatory bowel disease and they've had a stroke. Is that- are these related? Are these unrelated? And I thought the articles kind of answer all of these questions. What would I say beyond this patient has disease X and is on drug Y? Well, look up in this issue disease X and see what the neurology can be, common and rare and how often it's associated, how often it's the presenting feature, how often it means the treatment is failing, etc. I thought, I'm not sure there's much to say there. That's about a paragraph. And I thought, well, let's think even more broadly about neurologic consultation. And as you know, I like to think about diagnostic reasoning and clinical reasoning. And we talk a lot about framing bias right? And I think that is very common in consultative neurology because we'll be told in the consult or in the page or E-consult or whatever it is, this is a blank-year-old blank with a history of blank on treatment blank. And right away your mind is starting to say, oh, well, the patient just had heart disease, or, the patient is nine months pregnant, or, the patient is on an immune checkpoint inhibitor. And whether you want to do it or not, your mind is associating the patient's neurology with that. And it's- even if we know we're framing or anchoring, it's hard to kind of pull away from that. And most of the time, common things being common, a patient with cancer develops new neurology, It's probably the cancer, the treatment, or sometimes a paraneoplastic syndrome. But I've definitely found if you do a lot of inpatient neurology and a lot of consults that you're seeing so much and you have no choice but to apply these heuristics, because you're seeing a lot of volume quickly and the patients are in the hospital or they're being closely followed and outpatient setting by another specialist. You presume if you didn't get it quite right the first time, it's going to come back to you. And there's a little bit of difficulty figuring out, this is a case, actually, of all the altered mental status in acutely ill patients I got today, this is the one I should dig deeper in that I think this could turn out to be a stroke or encephalitis as opposed to delirium. I felt like that I really haven't approached that except knowing that it's easy to fall into traps. And so, I started to think about framing bias. You know, we talked about if we become aware of our biases, right, we're better at not falling prey to them. But it's subconscious. So, we might be applying it without even realizing, or even saying, I might be framing this case the wrong way, you can go right on framing it the wrong way. So, I want to kind of get a little more granular on what types of framing biases actually are relevant, specifically, to the console setting. And so, I tried to come up with a few more specific examples and try to think about ways that we could at least have a quick, if our knee-jerk is to associate primary disease X that the patient has or primary treatment X with neurologic symptom Y, what's at least a quick counter-knee jerk to say, what if it could be something else? So, for example, one of them I call "low signal-to-noise ratio bias." Altered mental status in the acutely ill hospitalized patient. What would you say, Lyell? 99 out of 100- 99.9 out of 100, it's not a primary neurologic disease. Is that fair to say? Dr Jones: Very high, yep. I agree. Dr Berkowitz: Yeah. But could it be a stroke? Could it be non-convulsive status epilepticus, meningitis encephalitis? So, how do we sort of counteract low signal-to-noise ratio bias, acknowledging it exists, acknowledging most of the time there is a low signal-to-noise, that it's not going to be neurology---to just for example, use the time course. This is pretty acute. Have I convinced myself this is not a stroke or a seizure or an acute neurologic infection? And if I'm not sure at the bedside, should I err on the side of more testing? Or the "curbside bias," as I call when your colleague just sends you a text message on your phone, No need to even open the chart, Dr Jones. Patient had a cerebellar stroke. Incidental. They're here for something else. Aspirin, right? Just like a super tentorial stroke. And you might reply thumbs up. And then imagine you open the CT scan and it's a huge cerebellar stroke with fourth ventricular compression- and patient can hide a lot of stroke back there, might just have a little ataxia. You were curbsided and that framed you to think, oh, they asked me, is aspirin okay for a cerebellar stroke and I said yes, without realizing actually the question should have been posed is, how do you manage a huge stroke with mass effect in the posterior fossa? So, these types of biases, I come up with five of them, I won't go through all of them. I'm in the article to sort of acknowledge for the reader, most of the time it's going to be what you look up in this issue, but how to think about the times where it might not be and how to be more precise about what framing is and different types of framing that occur specifically in the consultant arena. Dr Jones: And I think the longer we practice, the more of those low-frequency exceptions that you see. And, you know, and then it sticks in our mind and sometimes the bias swings the other way; people, you know, think primarily about the low frequency. And so, it's tricky. And what I really enjoyed about that article, we started talking about this probably more than a year ago, and more than a year ago, I would say relatively few clinicians were using a now widely popular large language model for clinical decision-making; we won't name the model. And now I think most clinicians are using it almost every day, right? And I think it puts a premium on how to think and how to engage with the patient, and less about the facts and the lists that a lot of conventional medical education really is derived from. So, I really appreciate that article. We can pat ourselves in the back. We had some foresight to put it in the issue, and I think it's a great addition to it. Dr Berkowitz: Thank you. Dr Jones: So, the list of potential topics when we think about the neurologic manifestations of systemic disease, we tend to break it down by organ systems, right? But the amount of things that could end up in the issue is almost infinite. Is there anything that, when you were putting this issue together---either in terms of the topics or editing the articles---is there anything that you wanted to include, but we just didn't have room? Dr Berkowitz: I certainly won't say we covered everything, but I will say we were able to recruit a fantastic team of authors. And as you and I also talked about at the beginning, although you could say, we're doing the movement disorders issue, let's find all the top movement disorders folks who are expert specialists in this field, there's not really a neurohematologist or a neurogastroenterologist out here. So, you and I put our heads together to think of phenomenal general neurologists in most cases, some subspecialists who know a lot about this but were also excited to read a lot more about it and assemble the existing knowledge by the practicing neurologist for the practicing neurologist. And I think with that approach and letting folks have kind of, you know, I asked some specific questions. These are topics I hope you'll cover. These are vexing questions in this area. I hope you'll find some answers to how often can this neurology be the primary feature of this rheumatologic disease with no systemic manifestations and when should we look or as we mentioned, the complicated endocarditis consult. I won't say we covered everything. This could be, and is, textbook-sized, and there are textbooks on this topic. But I think on the contrary, authors came back and had sections on things that I might not have thought to ask- to cover. Dr Sarah LaHue, my colleague here at UCSF, I asked for an article, as traditionally in this issue, on the neurology of pregnancy in the postpartum state and included, I think probably for the first time in Continuum, a fantastic review of neurologic considerations in patients in menopause, which I'm not sure has been covered before. So, things that I wouldn't have even thought to ask for. Our authors came back with some fantastic stuff. And the ICU article by Dr Shivani Ghoshal, instead of focusing just on altered mental status in the ICU, weakness in the ICU---those are all in there---I also asked her to discuss complications of procedures in the ICU. How often do procedures in the ICU cause local neuropathies or vascular injury, these types of things. Dr Jones: Yeah, me too. And I guess that's a great advertisement, that there probably are things that we didn't cover, but if there are, we can't think of them. We've done as best as we can. So now let's come back to our Continuum Audio trivia question for our listeners. And I'll repeat the question: what neurologic complication can occur from correcting hyperglycemia too quickly? And I actually think there might be two correct answers to this one. Dr Berkowitz, what do you think? Dr Berkowitz: Yeah, I was thinking of two things. I hope these are the things you're thinking of as well. One is what I think used to be referred to as insulin neuritis, sort of an acute painful small fiber neuropathy from after the initiation of insulin, I think also called treatment-induced diabetic neuropathy or something of that nature. And then the other one described, defined and classified by your colleagues there in Rochester, the diabetic lumbosacral radiculoplexis neuropathy or Bruns-Garland syndrome or a diabetic amyotropy, I think, can also---if I'm not mistaken---also occur in this context; you should have weight loss in association with diet treatment of diabetes. But how did I do? Dr Jones: Yeah, you win the prize, the first-ever prize. There's no monetary value to the prize, but pride, I think, is a good one. Yeah, those were the two I was thinking of. The treatment-induced neuropathy of diabetes is really nicely covered in Dr Rafid Mustafa's article on the neurologic complications of endocrine disorders. It's a rare condition characterized by the acute/subacute onset of diffuse neuropathic pain and some usually some autonomic dysfunction. And it occurs when you have rapid and substantial reductions in blood glucose levels. And you can almost map it out. There was a study from 2015 which is referenced in the article, which found that a drop in hemoglobin A1c of 2 to 3% over three months confers about a 20% absolute risk of developing this treatment-induced neuropathy of diabetes, and a drop of more than 4%, more than 80% risk. So, very substantial. And then in the other---we see this commonly in patients with diabetic lumbosacral radiculoplexis neuropathy---they have the subacute onset of usually asymmetric pain and weakness in the lower limbs that tends to occur more frequently in patients who have had recent better control of their sugar. We can also see it in the upper limbs too. So, you get a perfect score. Dr Berkowitz, well done. Again, I want to thank you. I want to thank you for such a great issue, a great article to kick off the issue, and a great discussion of the neurology of systemic disease. Today I learned a lot talking today, I learned a lot reading the issue. Really grateful for your leadership of putting it together, pulling together a really great author panel, and I think it will come in handy not just for our junior readers and listeners, but also our more experienced subscribers as well. Dr Berkowitz: Thank you so much. Like I said, it was a big honor to be invited to guest edit this issue. I've read it every three years since I started residency. It's always one of my favorite issues. As you said, a manual for consultative neurology, and I learned a ton from our authors and really appreciate the opportunity to work with you and the amazing Continuum team to bring this from an idea, as you said, probably over a year ago to a printed issue. So, thanks again, Lyell. Dr Jones: Thank you. And again, we've been speaking with Dr Aaron Berkowitz, guest editor of Continuum's most recent issue on the neurology of systemic disease. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

Medical missionaries often feel powerful emotional burden from moral injury, and it is a leading cause of departure from the mission field. But we have learned proven methods of preventing and dealing with moral injury. Use God’s powerful methods to protect yourself and your team, and to grow in wisdom and spirit!

This episode covers headaches in children.Written notes can be found at https://zerotofinals.com/paediatrics/neurology/headaches/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Send us a textIn this episode, Dr. Amy Gelfand, a child neurologist specializing in pediatric headaches, discusses the complexities and treatment of migraines in children. Gelfand explains the genetic nature of migraines and their commonality among kids, noting triggers like menstrual cycles and changes in sleep patterns. She elaborates on distinguishing features of migraines and provides insight into preventive and acute treatments, including NSAIDs, triptans, neuromodulation devices, and supplements. The discussion also covers the importance of a regular schedule, the benefits of cognitive behavioral therapy (CBT), and recent advancements in migraine-specific medications. Dr. Gelfand emphasizes the significant progress in migraine treatment and encourages families to consult specialists for personalized care.About Dr Gelfand:Dr. Amy Gelfand is a pediatric neurologist who specializes in diagnosing and treating children with a variety of headache disorders, as well as those with childhood periodic syndromes (such as abdominal migraine), which may be precursors to migraine headache later in life. Her research focuses on the epidemiology of pediatric migraine and childhood periodic syndromes.Gelfand received her medical degree from Harvard Medical School. She completed residencies in pediatrics and child neurology at UCSF.Gelfand has received a teaching award from the UCSF pediatric residency program and writing awards from the medical journal Neurology. She is a member of the American Academy of Neurology, Child Neurology Society and American Headache Society.Your Child is Normal is the trusted podcast for parents, pediatricians, and child health experts who want smart, nuanced conversations about raising healthy, resilient kids. Hosted by Dr. Jessica Hochman — a board-certified practicing pediatrician — the show combines evidence-based medicine, expert interviews, and real-world parenting advice to help listeners navigate everything from sleep struggles to mental health, nutrition, screen time, and more. Follow Dr Jessica Hochman:Instagram: @AskDrJessica and Tiktok @askdrjessicaYouTube channel: Ask Dr Jessica If you are interested in placing an ad on Your Child Is Normal click here or fill out our interest form.-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditi...

Lindsey Gurin, MD, discusses how clinicians can approach patients whose symptoms fall at the intersection of psychiatry and neurology. Drawing on her work with traumatic brain injury, PTSD, and persistent post-concussive symptoms, she explains why attempts to separate psychological trauma from neurological injury often obscure what patients actually need.The conversation explores identity disruption after brain injury, the unintended effects of rigid recovery timelines, and the importance of continuity in understanding symptoms over time. Dr. Gurin also discusses how neurodevelopmental traits such as ADHD shape vulnerability and treatment response, when stimulant medications can be appropriate after concussion, and why breaking complex presentations into treatable components often matters more than assigning a single diagnosis.Lindsey Gurin, MD, is Assistant Professor in the Departments of Neurology, Psychiatry, and Rehabilitation Medicine at NYU Langone Health, and Director of the Neurology/Psychiatry Residency Program.▶️ Watch Insights on Psychiatry on YouTube00:00 Brain Injury and Identity01:27 What Is the Psychiatry–Neurology Double Board?02:41 Why PTSD and TBI Overlap03:28 What “Shell Shock” Really Means06:00 When Concussion Symptoms Don't Go Away07:25 Life Before vs After Brain Injury08:46 ADHD as a Hidden Risk Factor10:28 Using Stimulants After Brain Injury12:40 Rethinking “Post-Concussion Syndrome”13:27 The Future of Neuropsychiatric CareThis episode is intended for psychiatrists and other clinicians caring for patients with complex neuropsychiatric presentations at the intersection of psychiatry and neurology.This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

When your gut heats up and your brain starts to ache, it's not random — it's a message. A flare-up in your gut can echo upward, shifting your brain chemistry, amplifying inflammation, and lowering your migraine threshold.In this episode of Migraine Heroes Podcast, host Diane Ducarme connects the dots between digestive distress and neurological pain — helping you understand why gut trouble so often becomes head trouble.You'll discover:

The February 2026 recall features four previously posted episodes on multiple sclerosis. The episode begins with a conversation with Dr. Wallace J. Brownle discussing whether dissemination in time is essential to diagnois relapsing MS. The discussion continues with Dr. Daniel Ontaneda regarding the 2024 revisions of the McDonald criteria for diagnosing multiple sclerosis. The episode then transitions into a conversation with Dr. Jiwon Oh about BTK inhibitors and recent data on tolebrutinib in multiple sclerosis. The episode concludes with Dr. Sandra Vukusic addressing the differences in disease-modifying therapies for female versus male patients with multiple sclerosis.  Podcast link: Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing MS 2024 McDonald Criteria  BTK Inhibitors in Multiple Sclerosis Treatment Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis Podcast article: Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis  Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria  Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis  Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis  Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis Disclosures can be found at Neurology.org. 

This episode covers breath holding spells.Written notes can be found at https://zerotofinals.com/paediatrics/neurology/breathholdingspells/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Dr. Tesha Monteith and Dr. Michael Eller discuss the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.  Show citation: Eller MT, Schwarzová K, Gufler L, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025;105(2):e213852. doi:10.1212/WNL.0000000000213852  Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Michael Eller from the Department of Neurology Medical University of Innsbruck, Austria on the neurology podcast on his paper, CGRP Targeted Migraine Therapies in Patients with Vascular Risk Factors or Stroke: A Review. Hi, Michael. Dr. Michael Eller: Hello. Dr. Tesha Monteith: Why don't you summarize your general approach to use of CGRP targeted therapies in patients that might be at risk for vascular events when considering safety? Dr. Michael Eller: Yeah. About acute vascular events, we should stop CGLP targeted drugs immediately. When we come to post-stroke, we should reassess the necessity of these targeted treatments after recovery. We suggest a minimum of three months pause after ischemic stroke to allow early recovery and remodeling, and then restart only after individualized benefit risk review. In high-risk primary prevention, so no stroke yet, but elevated risk, if the patients are 65 years or older with established cardiovascular disease, we should prefer traditional preventives. And if CGLP targeted therapy is essential, we should consider Gepants cautiously due to their shorter half lives. We should avoid CGLP targeted treatments in small vessel disease, distal stenosis, Raynaud's phenomenon, and uncontrolled hypertension. For acute migraine treatment, we can consider gepants or ditans as alternatives to triptans and NSAIDs in relevant stroke risk or post-stroke patients, individualized to comorbidities. Dr. Tesha Monteith: Great. And we should say that the label updates include hypertension and Raynaud's phenomenon as potential vascular complications. Otherwise, these are more theoretical risks based on what we know about CGRP. Dr. Michael Eller: Yes, I totally agree because large studies did not show any elevated cardiovascular risk signals. And for post-marketing databases, we did not see any elevated cardiovascular risk so far. However, in pre-clinical settings, studies showed large infarct size in pretreated mice. Dr. Tesha Monteith: Great. Well, thank you again for doing this work. It was a phenomenal read and congratulations. Dr. Michael Eller: Thank you. Dr. Tesha Monteith: This is Tesha Monteith. Thank you for listening to the Neurology Minute.

Send us a textForget the assumption that modern neurology only thrives where resources are abundant. We sit down with Dr. Daniel Ontaneda and Dr. Nelson Maldonado—two Ecuadorian neurologists driving change across Latin America—to explore how world-class care is built on clinical craft, cultural fluency, and relentless advocacy. From bedside localization when the MRI is down to expanding stroke thrombolysis from a handful of cases to hundreds, their stories reveal a system where expertise is abundant but access can lag—and how that gap is closing.We retrace Dan's journey from Quito to leading-edge MS research, and Nelson's decision to return home to build services few believed possible. Together they unpack what training looks like across the region, including long-format medical school, rural service, and residencies that demand deep exam skills. We compare public and private systems in Ecuador, break down why patients often want clear directives rather than options, and examine how cultural beliefs and language shape adherence. The conversation digs into MS treatment in low- and middle-resource settings, the rise of highly effective disease-modifying therapies, and the pragmatic use of cost-effective options like rituximab.The episode also exposes a hidden threat: substandard medications entering through price-first procurement, undermining both acute care and chronic neurologic disease. Yet the momentum is real—regional MS registries, imaging collaborations that move faster than heavily regulated systems, and conferences that bring neurocritical care and MS experts under one roof. Even subspecialists practice broadly, treating Parkinson's disease, epilepsy, headache, and ICU cases in the same week, sharpening an exam-first mindset that delivers results.If you care about global neurology, stroke systems of care, MS access, and the practical ethics of delivering evidence-based treatment under constraints, this conversation will challenge assumptions and spark ideas. Subscribe, share with a colleague, and leave a review telling us where neurology should invest next.Support the showHosts:Dr. Nupur Goel is a third-year neurology resident at Mass General Brigham in Boston, MA. Follow Dr. Nupur Goel on Twitter @mdgoels Dr. Blake Buletko is a vascular neurologist and program director of the Adult Neurology Residency Program at the Cleveland Clinic in Cleveland, OH. Follow Dr. Blake Buletko on Twitter @blakebuletko Follow the Neurophilia Podcast on Twitter and Instagram @NeurophiliaPod

In this episode of the Brain & Life Podcast, co-host Dr. Katy Peters is joined by award-winning actor and playwright Michael Patrick, who shares his journey from studying science at Cambridge to becoming a celebrated actor. Michael also discusses his diagnosis of Motor Neuron Disease (MND), his participation in a clinical trial, and how he continues to find hope and support from his network. Dr. Peters is then joined by Dr. Matthew Harms, an Associate Professor of Neurology at Columbia University Irving Medical Center. Dr. Harms explains the complexities of diagnosing Motor Neuron Disease and ALS, the genetic factors involved, and the importance of early detection and treatment. He also discusses the importance of advocacy and what exciting research is happening now.   Additional Resources What are motor neuron diseases? Developments in ALS Research Michael Patrick: Actor and Writer   Brain & Life Podcast Episodes on These Topics Focusing on Hope: Answering your ALS Questions with Dr. Rick Bedlack Making the Years Count with Brooke Eby, Influencer Living with ALS Finding Strength in ALS Advocacy with Podcaster Lorri Carey We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media:   Guests: Michael Patrick @michaelpatrick314; Dr. Harms @osdib_cuimc Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

Dr. Stacey Clardy talks with Dr. John Ney about the prevalence, disability burden, and societal impact of neurologic disorders in the U.S.  Read the related article in JAMA.  Disclosures can be found at Neurology.org. 

In late 1916, while treating a group of patients at his psychiatric clinic at the University of Vienna, Dr. Constantin von Economo began noticing the appearance of strange symptoms that he could not account for. At the same time, in France, Rene Cruchet began noticing similarly strange and unexpected symptoms in his patients. Though the two men had never met and knew nothing of one another's patients, they would come to learn they were both witnessing the emergence of a new mysterious disease that would soon affect millions of people around the world.The illnesses documented by von Economo and Cruchet would eventually come to be know as encephalitis lethargica, or sleeping sickness, a strange condition that caused profound lethargy, hypersomnia, and a wide range of other frightening symptoms. Between 1919 and the early 1930s, millions of people all around the world contracted the illness, with nearly half of all cases resulting in death, and many more suffering long-term effects; yet a cause of the illness has never been established and the terrifying epidemic appears to have faded from memory not long after the disease itself ostensibly disappeared. ReferencesBrook, Harry Ellington. 1921. "Care of the body." Los Angeles Times, March 6: 18.Crosby, Molly Caldwell. 2011. Asleep: The Forgotten Epidemic that Remains One of Medicine's Greatest Mysteries. New York, NY: Penguin Publishing Group.Hassler, Dr. William. 1919. "No sleeping sickness in S.F." San Francisco Examiner, March 10: 1.Hoffman, Leslie A., and Joel A. Vilensky. 2017. "Encephalitis lethargica: 100 years after the epidemic." Brain: A Journal of Neurology 2246-2251.Montreal Star. 1920. "Sleeping sickness puzzling doctors." Montreal Star, January 15: 3.New York Times. 1936. "Awakens from sleep continuing 440 days." New York Times, June 14: 13.R.R. Dourmashkin, MD. 1997. "What caused the 1918-30 epidemic of encephalitis lethargica?" Journal of the Royal Society of Medicine 515-520.Sacks, Oliver. 1973. Awakenings. New York, NY: Vintage.San Francisco Examiner. 1919. "New sleeping sickness hits S.F. residents." San Francisco Examiner, March 14: 1.—. 1921. "Ten succumb to sleeping sickness." San Francisco Examiner, August 18: 13.Western Morning News. 1919. "Notices." Western Morning News, January 1: 1.Williams, David Bruce. 2020. "Encephalitis Lethargica: The Challenge of Structure and Function in Neuropsychiatry." Archives of Medicine and Health Sciences 255-262.Wright, Oliver. 2002. "His life passed in a trance but his death may solve medical."  The Times, December 14. Cowritten by Alaina Urquhart, Ash Kelley & Dave White (Since 10/2022)Produced & Edited by Mikie Sirois (Since 2023)Research by Dave White (Since 10/2022), Alaina Urquhart & Ash KelleyListener Correspondence & Collaboration by Debra LallyListener Tale Video Edited by Aidan McElman (Since 6/2025) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.